Transfusion-Associated Graft-vs-Host Disease

Rossi's Principles of Transfusion Medicine: Fourth Edition

Volumn , Issue , 2009, Pages 847-857

  Levine, John E ^a   Ferrara, James L M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84991434373     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303513.ch54     Document Type: Chapter

References (144)

1. Billingham RE. The biology of graft-versus-host reactions. Harvey Lect 1966;62:21-78.
2. Dey BR, Yang YG, Szot GL, et al. Interleukin-12 inhibits graft- versus-host disease through an Fas-mediated mechanism associated with alterations in donor T-cell activation and expansion. Blood 1998;91:3315-22.
3. Duffner UA, Maeda Y, Cooke KR, et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol 2004;172:7393-8.
4. Reddy P, Teshima T, Kukuruga M, et al. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J Exp Med 2001;194:1433-40.
5. Teshima T, Reddy P, Lowler KP, et al. Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8 alpha( + ) dendritic cells and reduces experimental acute graft- versus-host disease. Blood 2002;99:1825-32.
6. Csencsits KL, Bishop DK. Contrasting alloreactive CD4+ and CD8+ T cells: There's more to it than MHC restriction. Am J Transplant 2003;3:107-15.
7. Sprent J, Schaefer M, Gao EK, Korngold R. Role of T cell subsets in lethal graft-versus-host disease (GVHD) directed to class I versus class II H-2 differences. I. L3T4+ cells can either augment or retard GVHD elicited by Lyt-2+ cells in class I different hosts. J Exp Med 1988;167:556-69.
8. Bachmann MF, Kopf M. Balancing protective immunity and immu- nopathology. Curr Opin Immunol 2002;14:413-19.
9. Matzinger P. The danger model: A renewed sense of self. Science 2002;296:301-5.
10. Tan JK, O'Neill HC. Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity. J Leukoc Biol 2005;78:319-24.
11. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-57.
12. Lu Y, Sakamaki S, Kuroda H, et al. Prevention of lethal acute graft- versus-host disease in mice by oral administration of T helper 1 inhibitor, TAK-603. Blood 2001;97:1123-30.
13. Lin MT, Storer B, Martin PJ, et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 2003;349:2201-10.
14. Lin MT, Storer B, Martin PJ, et al. Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: Synergism between IL-10 genotype of patient and IL-10 receptor beta genotype of donor. Blood 2005;106:3995-4001.
15. Cohen JL, Boyer O. The role of CD4 + CD25hi regulatory T cells in the physiopathogeny of graft-versus-host disease. Curr Opin Immunol 2006;18:580-5.
16. Duffner U, Lu B, Hildebrandt GC, et al. Role of CXCR3- induced donor T-cell migration in acute GVHD. Exp Hematol 2003;31:897-902.
17. Wysocki CA, Jiang Q, Panoskaltsis-Mortari A, et al. Critical role for CCR5 in the function of donor CD4 + CD25+ regulatory T cells during acute graft-versus-host disease. Blood 2005;106:3300-07.
18. Kagi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994;265:528-30.
19. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994;370:650-2.
20. Krammer PH. CD95's deadly mission in the immune system. Nature 2000;407:789-95.
21. Graubert TA, DiPersio JF, Russell JH, Ley TJ. Perforin/granzyme- dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest 1997;100:904-11.
22. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: Rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000;95:2754-9.
23. Brown GR, Lee E, Thiele DL. TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J^C57BL/6J X bm12)F1 mice. J Immunol 2002;168:3065-71.
24. Hill GR, Teshima T, Rebel VI, et al. The p55 TNF-alpha receptor plays a critical role in T cell alloreactivity. J Immunol 2000;164:656-63.
25. Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/ cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 1987;166:1280-9.
26. Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease. BCSH Blood Transfusion Task Force. Transfus M 1996;6:261-71.
27. Williamson LM, Stainsby D, Jones H, et al. The impact of universal leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusion-associated graft-versus- host disease. Transfusion 2007;47:1455-67.
28. Martin PJ, Hansen JA, Torok-Storb B, et al. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant 1988;3:445-56.
29. Atkinson K, Farrelly H, Cooley M, et al. Human marrow T cell dose correlates with severity of subsequent acute graft-versus-host disease. Bone Marrow Transplant 1987;2:51-7.
30. Muller S, Schulz A, Reiss U, et al. Definition of a critical T cell threshold for prevention of GVHD after HLA non-identical PBPC transplantation in children. Bone Marrow Transplant 1999;24:575-81.
31. Klein HG. Wolf in wolf's clothing: Is it time to raise the bounty on the passenger leukocyte? Blood 1992;80:1865-8.
32. Hayashi H, Nishiuchi T, Tamura H, Takeda K. Transfusion-associated graft-versus-host disease caused by leukocyte-filtered stored blood. Anesthesiology 1993;79:1419-21.
33. Akahoshi M, Takanashi M, Masuda M, et al. A case of transfusion- associated graft-versus-host disease not prevented by white cell- reduction filters. Transfusion 1992;32:169-72.
34. Farrugia A, Tan Y, Romeo A, et al. Relative efficiency of leucocyte removal procedures for the production of leucocyte-poor red cell concentrates assessed by flow cytometry. Vox Sang 1994;66:153-60.
35. Lelkens CC, Noorman F, Koning JG, et al. Stability after thawing of RBCs frozen with the high- and low-glycerol method. Transfusion 2003;43:157-64.
36. Lowenthal RM, Menon C, Challis DR. Graft-versus-host disease in consecutive patients with acute myeloid leukaemia treated with blood cells from normal donors. Aust N Z J Med 1981;11:179-83.
37. Weiden PL, Zuckerman N, Hansen JA, et al. Fatal graft-versus-host disease in a patient with lymphoblastic leukemia following normal granulocyte transfusion. Blood 1981;57:328-32.
38. Levine JE, Braun T, Penza SL, et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002;20:405-12.
39. Williamson LM, Warwick RM. Transfusion-associated graft-versus- host disease and its prevention. Blood Rev 1995;9:251-61.
40. Rubinstein A, Radl J, Cottier H, et al. Unusual combined immunodeficiency syndrome exhibiting kappa-IgD paraproteinemia, residual gut immunity and graft-versus-host reaction after plasma infusion. Acta Paediatr Scand 1973;62:365-72.
41. Klein C, Fraitag S, Foulon E, Raffoux C, et al. Moderate and transient transfusion-associated cutaneous graft-versus-host disease in a child infected by human immunodeficiency virus. Am J Med 1996;101:445-6.
42. Kruskall MS, Lee TH, Assmann SF, et al. Survival of transfused donor white blood cells in HIV-infected recipients. Blood 2001;98:272-9.
43. Brune T, Koch HG, Plumpe U, et al. Effect of pathological perinatal conditions on the maternofetal transfer of mononuclear cells. Fetal Diagn Ther 2002;17:110-14.
44. Brune T, Beier K, Exeler R, et al. Neonatal lymphocytes dominate against lymphocytes of their own mother but not against allogenic maternal or adult lymphocytes in bidirectional mixed lymphocyte cultures. Fetal Diagn Ther 2003;18:154-9.
45. Liley AW. Intrauterine transfusion of foetus in haemolytic disease. Br Med J 1963;2:1107-9.
46. Naiman JL, Punnett HH, Lischner HW, et al. Possible graft-versus- host reaction after intrauterine transfusion for Rh erythroblastosis fetalis. N Engl J Med 1969;281:697-701.
47. Parkman R, Mosier D, Umansky I, et al. Graft-versus-host disease after intrauterine and exchange transfusions for hemolytic disease of the newborn. N Engl J Med 1974;290:359-63.
48. Vietor HE, Hallensleben E, van Bree SP, et al. Survival of donor cells 25 years after intrauterine transfusion. Blood 2000;95:2709-14.
49. Vaidya S, Mamlok R, Daeschner CW, et al. Suppression of graft-versus-host reaction in severe combined immunodeficiency with maternal-fetal T cell engraftment. Am J Pediatr Hematol Oncol 1991;13:172-5.
50. Ohto H, Anderson KC. Posttransfusion graft-versus-host disease in Japanese newborns. Transfusion 1996;36:117-23.
51. Asai T, Inaba S, Ohto H, et al. Guidelines for irradiation of blood and blood components to prevent post-transfusion graft-vs.-host disease in Japan. Transfus Med 2000;10:315-20.
52. Douglas SD, Fudenberg HH. Graft versus host reaction in Wiskott- Aldrich syndrome: Antemortem diagnosis of human GVH in an immunologic deficiency disease. Vox Sang 1969;16:172-8.
53. Alain G, Carrier C, Beaumier L, et al. In utero acute graft-versus- host disease in a neonate with severe combined immunodeficiency. J Am Acad Dermatol 1993;29:862-5.
54. van Royen-Kerkhof A, Wulffraat NM, Kamphuis SS, et al. Nonlethal transfusion associated graft-versus-host disease in a severe combined immunodeficient patient. Bone Marrow Transplant 2003;32:1027-30.
55. Strobel S, Morgan G, Simmonds AH, Levinsky RJ. Fatal graft versus host disease after platelet transfusions in a child with purine nucleoside phosphorylase deficiency. Eur J Pediatr 1989;148:312-14.
56. Wintergerst U, Meyer U, Remberger K, Belohradsky BH. [Graft versus host reaction in an infant with DiGeorge syndrome]. Monatsschr Kinderheilkd 1989;137:345-7.
57. Berkel AI, Tinaztepe K. Graft-versus-host reaction manifested as toxic epidermal necrolysis in a patient with acute leukemia. Turk J Pediatr 1981;23:37-41.
58. Schmidmeier W, Feil W, Gebhart W, et al. Fatal graft-versus-host reaction following granulocyte transfusions. Blut 1982;45:115-19.
59. Kessinger A, Armitage JO, Klassen LW, et al. Graft versus host disease following transfusion of normal blood products to patients with malignancies. J Surg Oncol 1987;36:206-9.
60. Rosen RC, Huestis DW, Corrigan JJ Jr. Acute leukemia and granulocyte transfusion: Fatal graft-versus-host reaction following transfusion of cells obtained from normal donors. J Pediatr 1978;93:268-70.
61. Dinsmore RE, Straus DJ, Pollack MS, et al. Fatal graft-versus-host disease following blood transfusion in Hodgkin's disease documented by HLA typing. Blood 1980;55:831-4.
62. Remlinger K, Buckner CD, Clift RA, et al. Fatal graft-versus-host and probable graft-versus-graft reaction due to an unirradiated granulocyte transfusion after allogeneic marrow transplantation. Transplant Proc 1983;15:1725-8.
63. Woods WG, Lubin BH. Fatal graft versus host disease following a blood transfusion in a child with neuroblastoma. Pediatrics 1981;67:217-21.
64. Betzhold J, Hong R. Fatal graft-versus-host disease after a small leukocyte transfusion in a patient with lymphoma and varicella. Pediatrics 1978;62:63-6.
65. Labotka RJ, Radvany R. Graft-versus-host disease in rhabdomyosarcoma following transfusion with nonirradiated blood products. Med Pediatr Oncol 1985;13:101-4.
66. Kennedy JS, Ricketts RR. Fatal graft v host disease in a child with neuroblastoma following a blood transfusion. J Pediatr Surg 1986;21:1108-9.
67. Benson K, Marks AR, Marshall MJ, Goldstein JD. Fatal graft-ver- sus-host disease associated with transfusions of HLA-matched, HLA-homozygous platelets from unrelated donors. Transfusion 1994;34:432-7.
68. Decoste SD, Boudreaux C, Dover JS. Transfusion-associated graft- vs-host disease in patients with malignancies. Report of two cases and review of the literature. Arch Dermatol 1990;126:1324-9.
69. Williamson LM, Wimperis JZ, Wood ME, Woodcock B. Fludarabine treatment and transfusion-associated graft-versus-host disease. Lancet 1996;348:472-3.
70. Deane M, Gor D, Macmahon ME, et al. Quantification of CMV virae- mia in a case of transfusion-related graft-versus-host disease associated with purine analogue treatment. Br J Haematol 1997;99:162-4.
71. Hutchinson K, Kopko PM, Muto KN, et al. Early diagnosis and successful treatment of a patient with transfusion-associated GVHD with autologous peripheral blood progenitor cell transplantation. Transfusion 2002;42:1567-72.
72. Cheson BD. New prospects in the treatment of indolent lymphomas with purine analogues. Cancer J Sci Am 1998;4 (Suppl 2):S27-36.
73. Leitman SF, Tisdale JF, Bolan CD, et al. Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus. Transfusion 2003;43:1667-71.
74. Orlandi C, Frassetto A, Gnucci E, et al. Treatment of acute posttransfusion graft-versus-host disease (GVHD) with intravenous human immunoglobulins: A case report. J Eur Acad Dermatol Venereol 2006;20:760-1.
75. Gupta A, Bansal D, Dass R, Das A. Transfusion associated graft versus host disease. Indian Pediatr 2004;41:1260-4.
76. Hume HA, Preiksaitis JB. Transfusion associated graft-versus-host disease, cytomegalovirus infection and HLA alloimmunization in neonatal and pediatric patients. Transfus Sci 1999;21:73-95.
77. Lee CK, Gingrich RD, Hohl RJ, Ajram KA. Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation. Bone Marrow Transplant 1995;16:175-82.
78. Miura Y, Thoburn CJ, Bright EC, et al. Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): Interleukin 10 and Interferon gamma may be critical mediators for the development of autologous GVHD. Blood 2002;100:2650-8.
79. Sage D, Stanworth S, Turner D, Navarrete C. Diagnosis of transfusion-associated graft-vs.-host disease: The importance of short tandem repeat analysis. Transfus Med 2005;15:481-5.
80. Adeva Andany M, Martinez W, Arnal F, et al. Transfusion-associated graft-versus-host disease in a renal transplant recipient. Nephrol Dial Transplant 1994;9:196-8.
81. Deierhoi MH, Sollinger HW, Bozdech MJ, Belzer FO. Lethal graft- versus-host disease in a recipient of a pancreas-spleen transplant. Transplantation 1986;41:544-6.
82. Smith DM, Agura E, Netto G, et al. Liver transplant-associated graft-versus-host disease. Transplantation 2003;75:118-26.
83. Sola MA, Espana A, Redondo P, et al. Transfusion-associated acute graft-versus-host disease in a heart transplant recipient. Br J Dermatol 1995;132:626-30.
84. Kimball P, Ham J, Eisenberg M, et al. Lethal graft-versus-host disease after simultaneous kidney-pancreas transplantation. Transplantation 1997;63:1685-8.
85. van der Mast BJ, van den Dorpel MA, Drabbels JJ, et al. Transfusion-associated graft vs. host disease after donor-specific leukocyte transfusion before kidney transplantation. Clin Transplant 2003;17:477-83.
86. Weinstein A, Dexter D, KuKuruga DL, et al. Acute graft-versus- host disease in pancreas transplantation: A comparison of two case presentations and a review of the literature. Transplantation 2006;82:127-31.
87. Soejima Y, Shimada M, Suehiro T, et al. Graft-versus-host disease following living donor liver transplantation. Liver Transpl 2004;10:460-4.
88. Kamei H, Oike F, Fujimoto Y, et al. Fatal graft-versus-host disease after living donor liver transplantation: Differential impact of donor-dominant one-way HLA matching. Liver Transpl 2006;12:140-5.
89. Key T, Taylor CJ, Bradley JA, Taylor AL. Recipients who receive a human leukocyte antigen-B compatible cadaveric liver allograft are at high risk of developing acute graft-versus-host disease. Transplantation 2004;78:1809-11.
90. Shivdasani RA, Anderson KC. HLA homozygosity and shared HLA haplotypes in the development of transfusion-associated graft-ver- sus-host disease. Leuk Lymphoma 1994;15:227-34.
91. Petz LD, Calhoun L, Yam P, et al. Transfusion-associated graft- versus-host disease in immunocompetent patients: Report of a fatal case associated with transfusion of blood from a second- degree relative, and a survey of predisposing factors. Transfusion 1993;33:742-50.
92. McMilin KD, Johnson RL. HLA homozygosity and the risk of related-donor transfusion-associated graft-versus-host disease. Transfus Med Rev 1993;7:37-41.
93. Otsuka S, Kunieda K, Kitamura F, et al. The critical role of blood from HLA-homozygous donors in fatal transfusion-associated graft-versus-host disease in immunocompetent patients. Transfusion 1991;31:260-4.
94. Triulzi D, Duquesnoy R, Nichols L, et al. Fatal transfusion-associated graft-versus-host disease in an immunocompetent recipient of a volunteer unit of red cells. Transfusion 2006;46:885-8.
95. Agbaht K, Altintas ND, Topeli A, et al. Transfusion-associated graft-versus-host disease in immunocompetent patients: Case series and review of the literature. Transfusion 2007;47:1405-11.
96. Rososhansky S, Badonnel MC, Hiestand LL, et al. Transfusion- associated graft-versus-host disease in an immunocompetent patient following cardiac surgery. Vox Sang 1999;76:59-63.
97. Ahya R, Douglas JG, Watson HG. Transfusion associated graft versus host disease in an immunocompetent individual following coronary artery bypass grafting. Heart 1998;80:299-300.
98. Serefhanoglu K, Turan H, Saba T, et al. Transfusion-associated graft-versus-host disease in an immunocompetent individual following cardiac surgery. J Natl Med Assoc 2005;97:418-20.
99. Hisatomi K, Isomura T, Kawara T, et al. Changes in lymphocyte subsets, mitogen responsiveness, and interleukin-2 production after cardiac operations. J Thorac Cardiovasc Surg 1989;98:580-91.
100. Borgermann J, Friedrich I, Flohe S, et al. Tumor necrosis factoralpha production in whole blood after cardiopulmonary bypass: Downregulation caused by circulating cytokine-inhibitory activities. J Thorac Cardiovasc Surg 2002;124:608-17.
101. Hauser GJ, Chan MM, Casey WF, et al. Immune dysfunction in children after corrective surgery for congenital heart disease. Crit Care Med 1991;19:874-81.
102. Hatley RM, Reynolds M, Paller AS, Chou P. Graft-versus-host disease following ECMO. J Pediatr Surg 1991;26:317-19.
103. Ohto H, Anderson KC. Survey of transfusion-associated graft-ver- sus-host disease in immunocompetent recipients. Transfus Med Rev 1996;10:31-43.
104. Yasuura K, Okamoto H, Matsuura A. Transfusion-associated graft- versus-host disease with transfusion practice in cardiac surgery. J Cardiovasc Surg (Torino) 2000;41:377-80.
105. Aoun E, Shamseddine A, Chehal A, et al. Transfusion-associated GVHD: 10 years' experience at the American University of Beirut- Medical Center Transfusion 2003;43:1672-6.
106. Qu L, Triulzi DJ, Rowe DT, et al. Stability of lymphocytes and Epstein-Barr virus during red blood cell storage. Vox Sang 2007;92:125-9.
107. Chang H, Voralia M, Bali M, et al. Irreversible loss of donor blood leucocyte activation may explain a paucity of transfusion-associated graft-versus-host disease from stored blood. Br J Haematol 2000;111:146-56.
108. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment. Blood 1990;76:1464-72.
109. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991;28:250-9.
110. Sullivan KM, Mori M, Sanders J, et al. Late complications of allogeneic and autologous marrow transplantation. Bone Marrow Transplant 1992;10 (Suppl 1):127-34.
111. Deeg HJ, An tin JH. The clinical spectrum of acute graft-versus- host disease. Semin Hematol 2006;43:24-31.
112. Perrotta PL, Snyder EL. Non-infectious complications of transfusion therapy. Blood Rev 2001;15:69-83.
113. Brubaker DB. Transfusion-associated graft-versus-host disease. Hum Pathol 1986;17:1085-8.
114. Vogelsang GB, Lee L, Bensen-Kennedy DM. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med 2003;54:29-52.
115. Oto OA, Paydas S, Baslamisli F, et al. Transfusion-associated graft- versus-host disease. Eur J Intern Med 2006;17:151-6.
116. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991;324:667-74.
117. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: Pathobiology and management. Exp Hematol 2001;29:259-77.
118. Nevo S, Enger C, Swan V, et al. Acute bleeding after allogeneic bone marrow transplantation: Association with graft versus host disease and effect on survival. Transplantation 1999;67:681-9.
119. Snover DC, Weisdorf SA, Vercellotti GM, et al. A histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. Hum Pathol 1985;16:387-92.
120. Bombi JA, Nadal A, Carreras E, et al. Assessment of histopathologic changes in the colonic biopsy in acute graft-versus-host disease. Am J Clin Pathol 1995;103:690-5.
121. Quaglia A, Duarte R, Patch D, et al. Histopathology of graft versus host disease of the liver. Histopathology 2007;50:727-38.
122. Matsushita H, Shibata Y, Fuse K, et al. Sex chromatin analysis of lymphocytes invading host organs in transfusion-associated graft- versus-host disease. Virchows Arch B Cell Pathol Incl Mol Pathol 1988;55:237-9.
123. Tanei R, Ohta Y, Ishihara S, et al. Transfusion-associated graft- versus-host disease: An in situ hybridization analysis of the infiltrating donor-derived cells in the cutaneous lesion. Dermatology 1999;199:20-4.
124. MacMillan ML, Weisdorf DJ, Wagner JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus- host disease: Comparison of grading systems. Biol Blood Marrow Transplant 2002;8:387-94.
125. Cragg L, Blazar BR, Defor T, et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant 2000;6:441-7.
126. MacMillan ML, Weisdorf DJ, Davies SM, et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2002;8:40-6.
127. McCaul KG, Nevill TJ, Barnett MJ, et al. Treatment of steroid- resistant acute graft-versus-host disease with rabbit antithymocyte globulin. J Hematother Stem Cell Res 2000;9:367-74.
128. Arai S, Margolis J, Zahurak M, et al. Poor outcome in steroid- refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002;8:155-60.
129. Barr ML, Meiser BM, Eisen HJ, et al. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med 1998;339:1744-51.
130. Greinix HT, Knobler RM, Worel N, et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica 2006;91:405-8.
131. Levine JE, Paczesny S, Mineishi S, et al. Etanercept plus methyl- prednisolone as initial therapy for acute graft-versus-host disease. Blood 2008;111:2470-5.
132. Kuball J, Theobald M, Ferreira EA, et al. Control of organ transplant-associated graft-versus-host disease by activated host lymphocyte infusions. Transplantation 2004;78:1774-9.
133. Yasukawa M, Shinozaki F, Hato T, et al. Successful treatment of transfusion-associated graft-versus-host disease. Br J Haematol 1994;86:831-6.
134. Mori S, Matsushita H, Ozaki K, et al. Spontaneous resolution of transfusion-associated graft-versus-host disease. Transfusion 1995;35:431-5.
135. Pelszynski MM, Moroff G, Luban NL, et al. Effect of gamma irradiation of red blood cell units on T-cell inactivation as assessed by limiting dilution analysis: Implications for preventing transfusion- associated graft-versus-host disease. Blood. 1994;83:1683-9.
136. Holme S. Current issues related to the quality of stored RBCs. Transfus Apher Sci 2005;33:55-61.
137. Wagner SJ, Myrup AC. Prestorage leucoreduction improves several in vitro red cell storage parameters following gamma irradiation. Transfus Med 2006;16:261-5.
138. Anderson K. Broadening the spectrum of patient groups at risk for transfusion-associated GVHD: Implications for universal irradiation of cellular blood components. Transfusion 2003;43:1652-4.
139. Klein HG. Transfusion-associated graft-versus-host disease: Less fresh blood and more gray (Gy) for an aging population. Transfusion 2006;46:878-80.
140. Moroff G, Luban NL. The irradiation of blood and blood components to prevent graft-versus-host disease: Technical issues and guidelines. Transfus Med Rev 1997;11:15-26.
141. Goes EG, Borges JC, Covas DT, et al. Quality control of blood irradiation: Determination T cells radiosensitivity to cobalt-60 gamma rays. Transfusion 2006;46:34-40.
142. Report finds alternatives for blood irradiators, other radiation sources to improve national security. AABB Weekly Report 2008;14(8):1.
143. Luban NL. Prevention of transfusion-associated graft-versus-host disease by inactivation of T cells in platelet components. Semin Hematol 2001;38:34-45.
144. Roback JD, Conlan M, Drew WL, et al. The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections. Transfus Med Rev 2006;20:45-56.